Aug 09, 2016 11:00 am UTC| Business
RICHMOND, Va., Aug. 09, 2016 -- Synalloy Corporation (Nasdaq:SYNL), today announced net sales for the second quarter of 2016 of $34.9 million. This represents a decrease of $15.3 million or 30% when compared to net...
Kandi Technologies Reports Second Quarter 2016 Financial Results
Aug 09, 2016 11:00 am UTC| Business
Q2 2016 revenue increased 15.1% YoY to $55.2 millionQ2 JV’s EV products sales exceed expectations by 20%, reaching 7,200, a 61.9% YoY increaseQ2 2016 Non-GAAP net income increased 114.8% YoY to $10.5 million, or $0.22 EPS ...
AGTC to Present at the Wedbush PacGrow Healthcare Conference on August 16th, 2016
Aug 09, 2016 11:00 am UTC| Business
GAINESVILLE, Fla., Aug. 09, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare...
L.B. Foster Reports Second Quarter Operating Results
Aug 09, 2016 11:00 am UTC| Business
PITTSBURGH, Aug. 09, 2016 -- L.B. Foster Company (NASDAQ:FSTR), a leading manufacturer, fabricator, and distributor of products and services for rail, construction, energy and utility markets, today reported its second...
Antares Pharma Reports Second Quarter 2016 Operating and Financial Results
Aug 09, 2016 11:00 am UTC| Business
EWING, N.J., Aug. 09, 2016 -- Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating and financial results for the second quarter ended June 30, 2016. The Company reported revenue of $12.2 million and a net loss...
Nabriva Reports Second Quarter 2016 Financial Results
Aug 09, 2016 11:00 am UTC| Business
LEAP 2 clinical trial initiated in second quarter Reiterates expectation of top-line data from both CABP phase 3 trials in the second half of 2017 VIENNA, Austria and KING OF PRUSSIA, Pa., Aug. 09, 2016 -- Nabriva...
Selecta Biosciences Announces Second Quarter 2016 Financial Results and Provides Corporate Update
Aug 09, 2016 11:00 am UTC| Business
Demonstrated clinical activity in Phase 1 program of SEL-212Advanced two proprietary gene therapy programs based on the same SVP-Rapamycin immunotherapy as SEL-212Successfully completed Initial Public Offering with net...